Recursion Pharmaceuticals Inc. stock reached a 52-week low, closing at $2.98. The biotechnology company, with a market capitalization of $1.58 billion, now trades 58% below its 52-week high of $7.18.
The prevailing assumption in AI development has been straightforward: larger models trained on more data produce better results. Nvidia's latest release directly challenges that size assumption — and ...
Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...
Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, Recursion announced positive Phase 1b/2 results for REC-4881, which is its ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...
Add a description, image, and links to the javascript-2 topic page so that developers can more easily learn about it.
Many saw desktop impressions drop around Sept. 10. A working theory is that past spikes were inflated by bots loading 100-result pages. Google hasn’t commented yet. Google appears to have disabled the ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results